OVID News and Press, Ovid Therapeutics Inc. From 11/10/21

Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of precision and small-molecule CNS medicines A development program for soticlestat, which Ovid licensed to Takeda, has begun enrolling ...

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Boa...

A group of small biotech companies are warning President Biden, Rep. Nancy Pelosi (D-Calif.), Sen. Chuck Schumer (D.-N.Y.) and other top lawmakers about the negative effects a proposed drug pricing bill would have on their industry. In a letter, they say that government-dictated prices for dr...

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases, today announced that management will present in a virtual format at the ...

Company ends Q2 ’21 with cash and cash equivalents of $212.2 million Recent appointments to Company leadership strongly position Ovid to advance current and future neuroscience programs Ovid is actively pursuing business development opportunities to complement its neurosc...

The COVID-19 pandemic brought renewed interest in the biotech industry. Many company's that weren't even working on vaccines or treatments saw their shares rise. But there are also great biotech stocks that are not recognized by the market yet. Champions Oncology (CSBR) and Ovid Therapeutics ...

Because the spread of the coronavirus Delta variant in several countries is becoming a major concern, the biotech industry is expected to continue attracting investors’ attention. The industry’s role in finding cures for various other diseases should also sustain investorsȁ...

Ovid Therapeutics (OVID) announced the appointment of life sciences industry veteran Jason Tardio as the company's Chief Operating Officer, and made slew of leadership changes.Tardio has over 20 years of leadership experience in the life sciences industry and joined Ovid i...

Dr. Michael Poole to Join the Board of Directors Dr. Claude Nicaise Appointed Head of R&D and Jason Tardio Appointed Chief Operating Officer Dr. Amit Rakhit to Join the Scientific and Clinical Advisory Board NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Ovid Ther...

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at the L...